We are live on
!
Find out more
HP
HealthInvest Partners Portfolio holdings
AUM
$372M
1-Year Est. Return
59.89%
This Fund
S&P 500
This Quarter
Est. Return
+0.9%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$218M
AUM Growth
+$4.51M
(+2.1%)
Cap. Flow
+$3.13M
Cap. Flow
% of AUM
1.43%
Top 10 Holdings %
Top 10 Hldgs %
66.25%
Holding
22
New
4
Increased
3
Reduced
9
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CXRX
Concordia International Corp. Common Stock
CXRX
|
+$14.3M |
| 2 |
Cencora
COR
|
+$12.8M |
| 3 |
Cardinal Health
CAH
|
+$12.8M |
| 4 |
INSY
Insys Therapeutics, Inc.
INSY
|
+$11.5M |
| 5 |
GNC
GNC Holdings, Inc.
GNC
|
+$2.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FEIC
FEI COMPANY
FEIC
|
+$11.6M |
| 2 |
Bausch Health
BHC
|
+$9.73M |
| 3 |
LPNT
LifePoint Health, Inc.
LPNT
|
+$6.02M |
| 4 |
Supernus Pharmaceuticals
SUPN
|
+$4.36M |
| 5 |
Anika Therapeutics
ANIK
|
+$3.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 73.26% |
| 2 | Industrials | 7.6% |
| 3 | Financials | 5.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Anika Therapeutics
ANIK
$215M
| $22.1M | 10.15% |
412,588
-77,743
| -16% | -$3.66M |
|
|
GNC
2
DELISTED
GNC Holdings, Inc.
GNC
| $16.6M | 7.6% |
681,955
+95,000
| +16% | +$2.62M |
|
|
AMAG
3
DELISTED
AMAG Pharmaceuticals
AMAG
| $16.1M | 7.37% |
671,585
-69,000
| -9% | -$1.58M |
|
|
4
Supernus Pharmaceuticals
SUPN
$2.7B
| $13.4M | 6.14% |
657,533
-246,000
| -27% | -$4.36M |
|
|
GTS
5
DELISTED
Triple-S Management Corporation
GTS
| $13M | 5.97% |
560,110
+30,535
| +6% | +$710K |
|
6
Merck
MRK
$322B
| $12.9M | 5.92% |
234,857
-28,610
| -11% | -$1.52M |
|
|
7
Cencora
COR
$62B
| $12.7M | 5.82% |
+160,000
| New | +$12.8M |
|
|
FEIC
8
DELISTED
FEI COMPANY
FEIC
| $12.7M | 5.81% |
118,609
-121,000
| -50% | -$11.6M |
|
|
TARO
9
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $12.6M | 5.76% |
86,205
-7,800
| -8% | -$1.11M |
|
|
10
Cardinal Health
CAH
$53.7B
| $12.5M | 5.72% |
+160,000
| New | +$12.8M |
|
11
Charles River Laboratories
CRL
$11.3B
| $12.3M | 5.66% |
149,612
-28,695
| -16% | -$2.36M |
|
12
Elevance Health
ELV
$81.5B
| $12.3M | 5.66% |
93,900
| – | – |
|
|
LPNT
13
DELISTED
LifePoint Health, Inc.
LPNT
| $12.1M | 5.57% |
185,851
-88,579
| -32% | -$6.02M |
|
|
CXRX
14
DELISTED
Concordia International Corp. Common Stock
CXRX
| $11.7M | 5.36% |
+543,000
| New | +$14.3M |
|
|
SYNH
15
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $10.9M | 5% |
286,270
-38,000
| -12% | -$1.67M |
|
|
INSY
16
DELISTED
Insys Therapeutics, Inc.
INSY
| $10.2M | 4.68% |
+788,175
| New | +$11.5M |
|
17
OraSure Technologies
OSUR
$273M
| $2.81M | 1.29% |
475,771
+70,000
| +17% | +$497K |
|
18
ImmuCell
ICCC
$99.6M
| $1.16M | 0.53% |
168,323
| – | – |
|
|
ASRT
19
DELISTED
Assertio
ASRT
| – | – |
-3,333
| Closed | -$2.79M |
|
|
20
Bausch Health
BHC
$1.75B
| – | – |
-370,000
| Closed | -$9.73M |
|
|
SCLN
21
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
| – | – |
-236,288
| Closed | -$2.6M |
|
|
SSRG
22
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
| – | – |
-316,427
| Closed | -$3.12M |
|
Similar funds
KP
AWA
TCM
SAAM
SC
PAA
PC
BOCH
HealthInvest Partners's Q2 2016 Portfolio in Review
As of Q2 2016, HealthInvest Partners held 22 positions worth $218M, up 2.1% from $214M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
HealthInvest Partners's Q2 2016 filing shows 4 new, 3 increased, 9 reduced and 4 closed positions. Its largest new stake was Concordia International Corp. Common Stock: 543,000 shares worth $11.7M. The largest sale was FEI COMPANY, an estimated $11.6M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 66% a quarter earlier, followed by Industrials and Financials.
- HealthInvest Partners's largest Q2 2016 buy was Concordia International Corp. Common Stock: 543,000 shares worth $11.7M.
- HealthInvest Partners added most to GNC Holdings, Inc. in Q2 2016, an estimated $2.62M increase.
- HealthInvest Partners's biggest Q2 2016 reduction was FEI COMPANY, cutting an estimated $11.6M.
- HealthInvest Partners fully exited Bausch Health in Q2 2016, selling an estimated $9.73M.
- HealthInvest Partners's ten largest holdings make up 66% of its $218M portfolio in Q2 2016.
- HealthInvest Partners opened 4 new positions and closed 4 in Q2 2016.
- HealthInvest Partners's portfolio value rose 2.1% quarter-over-quarter to $218M.
Based on HealthInvest Partners's 13F filing for Q2 2016, filed 26 Jul 2016.